SCI时时刷

search
+
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Chimeric antigen receptor (CAR) T cells are revolutionizing cancer therapy, particularly for haematological malignancies, ...
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes
Approximately 40% of hormone receptor-positive (HR+), HER2-negative (HER2–) breast cancers harbour activating mutations in...
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?
The DESTINY-Breast06 trial investigated earlier and broader use of trastuzumab deruxtecan in patients with metastatic horm...
On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients?
A number of therapeutics that target mediators of signalling in the hypothalamic and brainstem regions that control appeti...
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
The B cell receptor (BCR) signalling pathway has an integral role in the pathogenesis of many B cell malignancies, includi...
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress
Author notesThese authors contributed equally: Shelley A. Jazowski, Rahul K. Nayak.Authors and AffiliationsDepartment of H...
Cadonilimab is effective and safe in recurrent cervical cancer
The standard-of-care (SOC) first-line treatment for patients with recurrent or metastatic cervical cancer is chemotherapy ...
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3
Competing interests Z.A.W. is a NAPOLI 3 study investigator; has received grants...
Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’
Competing interests C.N.-P. receives institutional research funding from Theriva...
The TOPGEAR trial — is chemoradiotherapy no longer a component of multidisciplinary care for gastric cancer?
Adjuvant chemoradiotherapy has a proven survival benefit for patients undergoing upfront resection of gastric cancer compa...
Lack of benefit from extended lymphadenectomy in muscle-invasive bladder cancer
Patients with muscle-invasive bladder cancer (MIBC) typically undergo radical cystectomy with bilateral pelvic lymphadenec...
MRI-based stratification reduces the risk of overdiagnosis of prostate cancer
Men with a serum PSA of >3.0 ng/ml are typically referred for further diagnostic investigations for prostate cancer; ho...
Author Correction: Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response
Author notesThese authors contributed equally: Christopher J. M. Williams, Allyson M. Peddle.These authors jointly supervi...
The high costs of anticancer therapies in the USA: challenges, opportunities and progress
The high costs of anticancer therapies in the USA: challenges, opportunities and progress
The USA spent $99 billion on orally administered and clinician-administered anticancer therapies (excluding supportive car...
Reflecting on the past 20 years in oncology
Reflecting on the past 20 years in oncology
The November 2024 issue of Nature Reviews Clinical Oncology marks the 20th anniversary of the journal. Here, we reflect on...
Two decades of advances in clinical oncology — lessons learned and future directions
Since the publication of the first issue of Nature Reviews Clinical Oncology, we have witnessed advances in multiple resea...
From the ESMO Congress 2024
From the ESMO Congress 2024
For a second consecutive year, members of the oncology community recently descended on Spain to hear the practice-changing...
Molecular imaging supports the development of multispecific cancer antibodies
Molecular imaging supports the development of multispecific cancer antibodies
Multispecific antibodies are engineered antibody derivatives that can bind to two or more distinct epitopes or antigens. U...
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response
Approximately 15% of locally advanced colorectal cancers (CRC) have DNA mismatch repair deficiency (dMMR), resulting in hi...
CABINET presents cabozantinib as a new treatment option for NETs
Patients with advanced-stage neuroendocrine tumours (NETs) have limited treatment options following disease progression af...
Adding perioperative durvalumab to neoadjuvant chemotherapy provides benefit in MIBC
Eligible patients with muscle-invasive bladder cancer (MIBC) typically receive cisplatin-based chemotherapy before radical...
A new standard of care for leiomyosarcoma
Patients with advanced-stage leiomyosarcoma, a type of soft-tissue sarcoma that occurs predominantly in uterine locations,...
New clinical trials in CUP and a novel paradigm in cancer classification
New clinical trials in CUP and a novel paradigm in cancer classification
Precision oncology has reached a milestone as data from two trials in which molecular profiling guided both site-specific ...
Vorasidenib: a new hope or a false promise for patients with low-grade glioma?
Despite recent FDA approval, the clinical utility of vorasidenib in the treatment of IDH-mutant low-grade gliomas remains ...
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
HER2-targeted therapies for patients with HER2+ breast cancer are rapidly evolving, offering a range of more complex and p...
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach
Despite documented evidence that ovarian cancer cells express immune-checkpoint molecules, such as PD-1 and PD-L1, and of ...
The age of foundation models
The age of foundation models
The development of clinically relevant artificial intelligence (AI) models has traditionally required access to extensive ...
Redefining priorities: a call for patient-centred cancer care and research
My close experience with cancer and interactions with other patients, caregivers and health-care providers have shaped my ...
Tumour mutational burden: clinical utility, challenges and emerging improvements
Tumour mutational burden: clinical utility, challenges and emerging improvements
Tumour mutational burden (TMB), defined as the total number of somatic non-synonymous mutations present within the cancer ...
Translating biological insights into improved management of endometrial cancer
Translating biological insights into improved management of endometrial cancer
Endometrial cancer (EC) is the most common gynaecological cancer among women in high-income countries, with both incidence...
阅读更多
format_indent_increase